RESUMEN
Background: Ovarian cancer is one of the top three most common cancers in women. Most are detected at an advanced stage, so early detection is essential. A scoring system can easily predict an ovarian malignancy. IOTA Simple Rules and RMI-4 are easy-to-implement scoring systems. This study aimed to evaluate the comparison between the accuracy of the IOTA simple rules scoring system and RMI-4 as a predictor of malignancy in ovarian tumor cases at Prof. Dr. IGNG Ngoerah general hospital. Methods: This study used a diagnostic trial design involving 120 ovarian tumor patients undergoing surgery at Prof. Dr. IGNG Ngoerah general hospital, with 100 patients meeting the inclusion criteria. The collected data were tabulated and analyzed using SPSS for Windows ver. 22. Results were considered significant if p?0.05. Results: From 100 patient samples who met the inclusion criteria, 60 subjects (60%) were ovarian tumors with benign histopathologic results, and 40 (40%) subjects were tumors with malignant histopathology. The majority of ovarian tumors with malignant histopathology were found in the age group >50 years (52.5%), the menopausal group (57.5%), and multiparity (70%). CA-125 levels above 35 U/ml are found in 90% of the population, with details of 92.5% found in populations with malignant histopathological tumors. The AUC values for RMI-4 and IOTA simple rules are 0.846 and 0.925, with the p value for each scoring system being <0.001. Conclusions: This study found that the IOTA simple rules scoring method has a better diagnostic value than RMI-4 scoring.
RESUMEN
Background: Neutrophil-to-lymphocyte ratio has been extensively studied as a prognostic factor for various diseases based on systemic inflammation. Premature rupture of membranes is an obstetric problem that does not only occur in term pregnancies but can also occur in preterm pregnancies. One of the main etiologies for premature rupture of membranes is inflammation. Knowing the difference in the NLR between preterm premature rupture of membranes and without PPROM is important to increase understanding of the crucial role of NLR in predicting the incidence of PPROM. Methods: This analytic case-control study compared NLR values ??in maternal blood serum between PPROM and without PPROM. This research was conducted in the emergency delivery room and obstetrics and gynecology outpatient clinic at Prof. dr. I.G.N.G. Ngoerah Hospital Denpasar from February to June 2022. Results: A high NLR in maternal blood serum may be a risk factor for PPROM. Patients with a high NLR had a 4.5 times greater likelihood of experiencing PPROM than those with a low NLR (OR=4.5; 95% CI=1.4-13.83; p=0.007). Conclusions: A high NLR in maternal blood serum is a marker of inflammation with an increased risk of 4.5 times for the occurrence of PPROM.
RESUMEN
Paclitaxel-cisplatin combination chemotherapy as first-line treatment of epithelial ovarian cancer (EOC) is known tocause myelosuppression that leads to decreased hemoglobin, platelet and leukocyte levels. This study aims to evaluatethe side effect of paclitaxel-cisplatin chemotherapy in EOC patients with hematologic status at Sanglah GeneralHospital, Denpasar. Observational retrospective research was conducted from February to May 2018. Samples wereEOC patients who underwent six cycles of paclitaxel-cisplatin chemotherapy at Sanglah General Hospital, BaliIndonesia from January 2015 to May 2018. Side effects of chemotherapy were seen from hemoglobin, platelet, andleukocyte data before and after six cycles of chemotherapy. Hematologic data were analyzed and compared usingPaired T-test with a level of confidence of 95% using the STATA version 14 software. Mean value of three hematologicparameters decreased after six cycles, including hemoglobin levels were 12.05–10.69 g/dl (p-value = 0.282); plateletlevels were 378.5–326.9 g/dl (p-value = 0.569) and leukocyte levels were 11.32–8.28 g/dl (p-value = 0.517). Therewere differences of hemoglobin, platelet, and leukocyte levels before the first and after the sixth cycle of chemotherapy.Low side effects of paclitaxel-cisplatin were observed in this study (Anemia grade 1).